Genome Care, a subsidiary of Theragen ETEX, said Friday that it plans to launch two new inspection services that can increase the implantation rate of artificial insemination in infertile women.
The two services are endometrial microbiome metagenomic analysis (EMMA) service and infectious chronic endometritis (ALICE) service developed by iGenomix, a Spanish genetic company.
The EMMA test examines the distribution of microorganisms in the endometrium through gene testing and identifies lactobacilli that are helpful for pregnancy, such as Lactobacillus.
The ALICE test, on the other hand, identifies the presence of bacteria that cause endometritis, a significant cause of infertility. The result of the test can help create optimal embryo implantation conditions in the body.
The two tests have been actively conducted in the U.S., Europe, and Japan since last year, Theragen ETEX said.
The new services come after the company launched the Endometriosis Acceptability Analysis (ERA) service, a test that can find the optimal implantation date, last month.
The company explained that all three tests could be performed simultaneously with a single biopsy.
"We recently launched a series of diagnostics related to solving infertility by using genome analysis technology," a Theragen ETEX official said. "The company hopes these services can help solve the problem of low fertility and help families suffering from infertility."
Genome Care also provides the various analyses, including a noninvasive antenatal anomaly test (NIPT) and embryonic chromosome aberration test (PGS) that uses the company’s next-generation sequence analysis (NGS) technology.
<© Korea Biomedical Review, All rights reserved.>